MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will highlight its pioneering modifier gene therapy platform at two major industry events in May 2025. The company will present its clinical advancements at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Salt Lake City, Utah, from May 4 to May 8, and the Retina World Congress in Ft. Lauderdale, Florida, from May 8 to May 11.
The presentations will focus on therapies such as OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy. The company remains on track towards filing three Biologics License Applications (BLAs) in the next three years. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications (BLAs)/Marketing Authorization Applications (MAAs) in the next three years,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen.
The ARVO Annual Meeting will feature key sessions showcasing Ocugen’s work, including a May 5 presentation on OCU400 led by Dr. Benjamin Bakall and a May 6 discussion on OCU410ST by Dr. Syed M. Shah. The ARVO spotlight will extend to evaluations of OCU410 for geographic atrophy, presented by leading experts.
At Retina World Congress, Ocugen’s Chief Medical Officer, Dr. Huma Qamar, will present the company’s findings and participate in expert panels. “We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” added Dr. Musunuri.
These appearances aim to spotlight Ocugen’s effort to advance science and innovation in gene therapy, addressing unmet medical needs in vision care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.